Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: A systematic review

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 108, Issue 9, 2014, Pages 538-549

  Babu, Bontha V ^a   Babu, Gopalan R ^b  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b NATIONAL INSTITUTE OF VIROLOGY   (India)

Author keywords

Compliance; Coverage; Global programme to eliminate lymphatic filariasis; Lymphatic filariasis; Mass drug administration; Systematic review

Indexed keywords

ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE;

ARTICLE; ATTITUDE TO HEALTH; AWARENESS; COMMUNITY CARE; DATA BASE; FEAR; HEALTH BEHAVIOR; HEALTH PROGRAM; HUMAN; INDIA; LYMPHATIC FILARIASIS; MASS DRUG ADMINISTRATION PROGRAM; PATIENT COMPLIANCE; RURAL AREA; SYSTEMATIC REVIEW; URBAN AREA; DISEASE ERADICATION; DRUG ADMINISTRATION; EDUCATION; ELEPHANTIASIS, FILARIAL; ENDEMIC DISEASES; HEALTH AUXILIARY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH EDUCATION; HOSPITAL ORGANIZATION; ORGANIZATION AND MANAGEMENT; PROCEDURES; PROGRAM DEVELOPMENT; PROGRAM EVALUATION;

COMMUNITY HEALTH SERVICES; COMMUNITY HEALTH WORKERS; DIETHYLCARBAMAZINE; DISEASE ERADICATION; DRUG ADMINISTRATION SCHEDULE; ELEPHANTIASIS, FILARIAL; ENDEMIC DISEASES; FILARICIDES; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HEALTH PLAN IMPLEMENTATION; HUMANS; INDIA; MEDICATION SYSTEMS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION;

EID: 84906053113     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru057     Document Type: Article

References (74)

1. WHO. Transmission assessment surveys in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement. Wkly Epidemiol Rec 2012;48:478-82.
2. WHO 50th World Health Assembly. Elimination of lymphatic filariasis as a public health problem. Resolution of the Executive Board of the WHO. WHA50.29. Geneva: WHO; 1997.
3. Government of India. National Health Policy 2002. New Delhi: Ministry of Health and Family Welfare, Government of India; 2002. pp. 1-39.
4. Government of India. Mass Drug Administration, National Vector Borne Diseases Control programme. New Delhi: Government of India; 2013. http://www.nvbdcp.gov.in/MDA.html [accessed 8 September 2013].
5. Ramaiah KD, Das PK, Appavoo NC et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop Med Int Health 2000;5:842-7.
6. Babu BV, Satyanarayana K. Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Trop Doct 2003;33:79-82.
7. Babu BV, Kar SK. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 2004;9:702-9.
8. Regu K, Showkath Ali MK et al. Mass drug administration against lymphatic filariasis: experiences from Kozhikode district of Kerala state. J Commun Dis 2006;38:333-8.
9. Babu BV, Mishra S. Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Trans R Soc Trop Med Hyg 2008;102:1207-13.
10. Cantey PT, Rout J, Rao G et al. Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. PLoS Negl Trop Dis 2010;4:e728.
11. Cantey PT, Rao G, Rout J, Fox LM. Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Trop Med Int Health 2010;15:224-31.
12. Nujum ZT. Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India. Int Health 2011;3:22-6.
13. Nandha B, Krishnamoorthy K, Jambulingam P. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India. Health Educ Res 2013;28:591-8.
14. Roy RN, Sarkar AP, Misra R et al. Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India. J Health Popul Nutr 2013;31:171-7.
15. Stolk WA, Swaminathan S, van Oortmarssen GJ et al. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Inf Dis 2003;188:1371-81.
16. Esterre P, Plichart C, Sechan Y, Nguyen NL. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop Med Int Health 2001;6:190-5.
17. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
18. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
19. Centre for Reviews and Dissemination. Systematic Reviews: CRD's guidance for undertaking reviews in health care. York: CRD, University of York; 2009. www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf [accessed 9 September 2013].
20. Kmet LM, Lee RC, Cook LS. Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields (HTA Initiative 13). Alberta, Canada: Alberta Heritage Foundation for Medical Research; 2004.
21. Budge PJ, Anthony KA, Sognikin E et al. Accuracy of coverage survey recall following an integrated MDA for lymphatic filariasis, schistosomiasis and soil-transmitted helminthiasis. 60th Annual Meeting of the American Society of Tropical Medicine and Hygiene 2011. Abstract no. 1574. https://www.astmh.org/AM/Template. cfm?Section=Abstracts_and_Education1&Template=/CM/ContentDisplay. cfm&ContentID=3724 [accessed 27 February 2014].
22. Ramaiah KD, Vijay Kumar KN, Chandrakala AV et al. Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Trop Med Int Health 2001;6:1062-9.
23. Babu BV, Behera DK, Kerketta AS et al. Use of an inclusive-partnership strategy in urban areas of Orissa, India, to increase compliance in a mass drug administration for the control of lymphatic filariasis. Ann Trop Med Parasitol 2006;100:621-30.
24. Ghosh S, Samanta A, Kole S. Mass drug administration of lymphatic filariasis: recent experiences from a district of West Bengal, India. Trop Parasitol 2013;3:67-71.
25. Koradhanyamath DM, Kulkarni P, Holla R. Coverage and compliance of MDA programme for lymphatic filariasis in Bidar district, Karnataka, India. Asian Pacific J Trop Dis 2012;2:290-2.
26. Ranganath BG. Coverage survey for assessing mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka, India. J Vector Borne Dis 2010;47:61-4.
27. Sunderam S, Haider S, Kashyap V et al. Evaluation of MDA for filariasis in the endemic District of Jharkhand. Indian J Prev Soc Med 2011;42:346-9.
28. Aswathy S, Beteena K, Leelamoni K. Mass drug administration against filariasis in India: perceptions and practices in a rural community in Kerala. Ann Trop Med Parasitol 2009;103:617-24.
29. Ravish KS, Ranganath TS, Riyaz BS. Coverage and compliance of mass drug administration for elimination of lymphatic filariasis in endemic areas of Bijapur district, Karnataka. Int J Basic Med Sci 2011;2:86-9.
30. Nirgude AS, Naik PR, Kondagunta N et al. Evaluation of coverage and compliance of mass drug administration programme 2011 for elimination of lymphatic filariasis in Nalgonda district of Andhra Pradesh, India. Natl J Community Med 2012;3:288-93.
31. Kumar P, Prajapati PB, Saxena D, Kaviswar AB, Kurian G. An evaluation of coverage and compliance of mass drug administration 2006 for elimination of lymphatic filariasis in endemic areas of Gujarat. Indian J Community Med 2008;33:38-42.
32. Remme JHF, Alleyne G, Plaisier AP. Estimation and prediction in tropical disease control: the example of onchocerciasis. In: Mollison D, editor. Epidemic Models: their Structure and Relation to Data. Cambridge: Cambridge University Press; 1995, pp. 372-92.
33. Plaisier AP, Stolk WA, Van Ooortmarssen GJ, Habbema JDF. Effectiveness of annual ivermectin treatment for Wuchereria bancrofti infection. Parasitol Today 2000;16:298-302.
34. Michael E, Malecela-Lazaro MN, Simonsen PE et al. Mathematical modelling and the control of lymphatic filariasis. Lancet Inf Dis 2004;4:223-34.
35. El-Setouhy M, Abd Elaziz KM, Helmy H et al. The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am J Trop Med Hyg 2007;77:1069-73.
36. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control / elimination of lymphatic filariasis. Bull World Health Org 1997;75:491-503.
37. Vaishnav KG, Patel IG. Independent assessment of mass drug administration in filariasis affected Surat city. J Comm Dis 2006;38:149-54.
38. Lahariya C, Mishra A. Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study. J Vector Borne Dis 2008;45:313-20.
39. Krentel A, Fischer PU, Weil GJ. A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis 2013;7:e2447.
40. Ramaiah KD, Vijay Kumar KN, Ravi R, Das PK. Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Ann Trop Med Parasitol 2005;99:243-52.
41. Gunawardena GS, Ismail MM, Bradley MH, Karunaweera ND. Impact of the 2004 mass drug administration for the control of lymphatic filariasis, in urban and rural areas of the Western province of Sri Lanka. Ann Trop Med Parasitol 2007;101:335-41.
42. Nandha B, Sadanandane C, JambulingamP, Das P. Delivery strategy of mass annual single dose DEC administration to eliminate lymphatic filariasis in the urban areas of Pondicherry, South India: 5 years of experience. Filaria J 2007;6:7.
43. Addiss D. The global alliance to eliminate lymphatic filariasis. The 6th meeting of the global alliance to eliminate lymphatic filariasis: a half-time review of lymphatic filariasis elimination and its integration with the control of other neglected tropical diseases. Parasit Vectors 2010;3:100.
44. Simonsen PE, Mwakitalu ME. Urban lymphatic filariasis. Parasitol Res 2013;112:35-44.
45. Ramaiah KD. Population migration: implications for lymphatic filariasis elimination programmes. PLoS Negl Trop Dis 2013;7:e2079.
46. Centers for Disease Control and Prevention. Mass drug administration for the elimination of lymphatic filariasis-Port-aU: Prince, Haiti, 2011- 2012. Morb Mortal Wkly Rep 2013;62:466-8.
47. Njomo DW, Mukko DA, Nyamongo NK, Karanja J. Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi town, Kenya. PLoS One 2014;9:e83413.
48. Babu BV. Social and behavioural issues of mass drug administration and morbidity management in the programme to eliminate lymphatic filariasis. In: Report of Scientific Working Group Meeting on Lymphatic Filariasis. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). Geneva: WHO; 2005. pp. 123-31. http://www.who.int/tdr/publications/tdR:researchpublications/ swg-lymphatiC:filariasis/en/index.html. [accessed 26 September 2013].
49. Wynd S, Melrose WD, Durrheim DN et al. Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature. Bull World Health Org 2007;85:493-8.
50. Babu BV, Rath K, Kerketta AS et al. Adverse reactions following mass drug administration during the programme to eliminate lymphatic filariasis in Orissa State, India. Trans R Soc Trop Med Hyg 2006;100:464-9.
51. McLaughlin SI, Radday J, Michel MCet al. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. Am J Trop Med Hyg 2003;68:568-73.
52. Lima AW, Medeiros Z, Santos ZC et al. Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil. Rev Soc Bras Med Trop 2012;45:745-50.
53. Bockarie MJ, Tisch DJ, Kastens W et al. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 2002;347:1841-8.
54. WHO. Global Programme to Eliminate Lymphatic Filariasis: Report of an Informal Meeting on Transmission Assessment Survey for Review of the Training Modules and Coordination for Country Support. WHO Headquarters, Geneva, 12-13 September 2012. Geneva: WHO; 2013. http://apps.who.int/iris/bitstream/10665/78614/1/ WHO_HTM_NTD_PCT_2013.6_eng.pdf [accessed 9 September 2013].
55. WHO. Monitoring and Epidemiological Assessment of Mass Drug Administration: a Manual for National Elimination Programme. WHO/HTM/NTD/PCT/2011.4. Geneva: WHO; 2011. http://whqlibdoc. who.int/publications/2011/9789241501484_eng.pdf [accessed 9 September 2013].
56. Rebollo MP, Bockarie MJ. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame. Expert Rev Anti Inf Ther 2013;11:723-31.
57. WHO. Global Programme to Eliminate Lymphatic Filariasis: Progress Report 2000-2009 and Strategic Plan 2010-2020. Geneva: WHO; 2010. http://whqlibdoc.who.int/publications/2010/9789241500722_ eng.pdf [accessed 9 September 2013].
58. WHO South East Asian Regional Office. Elimination of Lymphatic Filariasis in the South-East Asia Region. Report of the 8th Meeting of the Regional Programme Review Group (RPRG), Colombo, Sri Lanka, 28-29 April 2011. New Delhi: WHO Regional Office for South-East Asia; 2010. http://apps.searo.who.int/pds_docs/B4804.pdf [accessed 9 September 2013].
59. WHO South East Asian Regional Office. The Regional Strategic Plan for Elimination of Lymphatic Filariasis 2010-2015. New Delhi: WHO Regional Office for South-East Asia; 2010. http://www.searo.who.int/ about/administration_structure/cds/Lymphatic_Filariasis_SEA-CD-203.pdf [accessed 9 September 2013].
60. Haldar A, Mundle M, Harldar S et al. Mass DEC campaign for filariasis in a hyper endemic district of West Bengal. J Commun Dis 2001;33:192-7.
61. Mehta S, Shah V, Verma A et al. Comparison of coverage and compliance of mass drug administration 2012 in Surat, India. Natl J Community Med 2012;3:468-72.
62. Pattanshetty S, Kumar A, Kumar R et al. Mass drug administration to eliminate lymphatic filariasis in Southern India. Australasian Med J 2010;3:847-50.
63. Mukhopadhyay AK, Patnaik SK, Babu PS, Rao KNMB. Knowledge on lymphatic filariasis and mass drug administration (MDA) programme in filaria endemic districts of Andhra Pradesh, India. J Vector Borne Dis 2008;45:73-5.
64. Kumar A, Kumar P, Nagaraj K et al. A study on coverage and compliance of mass drug administration programme for elimination of filariasis in Udupi district, Karnataka, India. J Vector Borne Dis 2009;46:237-40.
65. Godale LB, Balaji UV. A Study on coverage evaluation, compliance and awareness of mass drug administration for elimination of lymphatic filariasis in Osmanabad district. Natl J Community Med 2012;3:391-4.
66. Mahalakshmy T, Kalaiselvan G, Parmar J, Dongre A. Coverage and compliance to diethylcarbamazine in relation to filaria prevention assistants in rural Puducherry, India. J Vector Borne Dis 2010;47:113-5.
67. Ranganath TS, Reddy NR. Elimination of lymphatic filariasis: mass drug administration in endemic areas of (Bidar district) Karnataka-2008. Indian J Community Med 2012;37:219-22.
68. Patel PK. Mass drug administration coverage evaluation survey for lymphatic filariasis in Bagalkot and Gulbarga districts. Indian J Community Med 2012;37:101-6.
69. Sinha N, Mallik S, Panja TK, Haldar A. Coverage and compliance of mass drug administration in lymphatic filariasis: a comparative analysis in a district ofWest Bengal, India. Global J Med Public Health 2012;1:3-10.
70. Jha SN, Mukherjee S, Goswami DN et al. Critical appraisal of mass drug administration (MDA) for lymphatic filariasis in a district of West Bengal. Indian J Prev Soc Med 2012;43:103-6.
71. Karmakar PR, Mitra K, Chatterjee A et al. A study on coverage, compliance and awareness about mass drug administration for elimination of lymphatic filariasis in a district of West Bengal, India. J Vector Borne Dis 2011;47:61-4.
72. Hussain M, Kumar DS, Nigudgi SR, Reddy S. Evaluation of mass drug administration campaign against lymphatic filariasis at Bidar district. J Evolution Med Dent Sci 2013;2:3561-7.
73. Shetty A, Santhuram AN, Nareshkumar SJ. Assessing coverage and compliance of mass drug administration under elimination of lymphatic filariasis program in Yadgir District, Karnataka. Intl J Med Sci Public Health 2012;1:71-4.
74. Sunish IP, Shriram AN, Sivan A et al. Lymphatic filariasis elimination programme in Andaman and Nicobar Islands, India: drug coverage and compliance post eight rounds of MDA. Trop Doct 2013;43:30-2.